BioSig Technologies, Inc. STEX Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Unvested Total Number Of Shares

Other financials

Income statement

See full

Revenue$13.0K+8.3%

Gross profit$12.0K-88.9%

Operating income-$35.7M-1,098%

Net income-$46.7M-1,560%

EPS (diluted)-$0.27-92.9%

Balance sheet

See full

Cash & equivalents$6.9M+84.0%

Total debt$15.0K-94.7%

Total equity$159.0M+6,003%

Total assets$173.3M+3,823%

Cash flow

See full

Operating cash flow-$10.2M-813%

CapEx$4.0K-93.1%

Free cash flow-$2.9M+29.4%

Valuation

See full

Market cap$88.66M-56.4%

P/S2,216.6×-5,967×

Profitability

See full

Gross margin80.1%+25.2pp

Operating margin-32,155%-14,261pp

Net margin-25,825%-11,789pp

FCF margin-97,216.7%-106,293pp

Returns & leverage

See full

Return on equity-627.1%—

Debt / equity0×—

Current ratio13.9×+11.5×

Where this comes from

Reported directly by BioSig Technologies, Inc. in its filing.

Tagged under the XBRL concept STEX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionUnvestedTotalNumberOfShares.

The official record: BioSig Technologies, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioSig Technologies, Inc.'s share based compensation arrangement by share based payment award equity instruments other than option unvested total number of shares.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioSig Technologies, Inc.'s share based compensation arrangement by share based payment award equity instruments other than option unvested total number of shares?: BioSig Technologies, Inc. (STEX) reported share based compensation arrangement by share based payment award equity instruments other than option unvested total number of shares of 678.7K in Q1 2026.